Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration ...

NDAQ:VKTX) Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Obese mice whose fat cells were genetically altered to produce an increased amount of the glucose-dependent insulinotropic ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

Semaglutide biosimilar is under clinical development by Leto Laboratories and currently in Phase II for Diabetes.

Corxel Pharmaceuticals (CORXEL), a leading biotech company committed to bringing innovative science and medicines to underserved patients with cardiometabolic diseases around the world, today ...

The molecule was built using Biomea Fusion’s FUSION™ System and is designed to regenerate insulin-producing beta cells with the aim to cure diabetes. Icovamenib’s proposed mechanism of ...

Antiobesity drugs are amazing people by how fast they melt off pounds. But it's no surprise to Richard DiMarchi.

today announced the acquisition of CX11 (also known as VCT220), an oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), for worldwide (excluding Greater China) development and ...

Glucagon-like peptide 1 receptor agonists ... combine the beneficial effects of two or more hormones into a single molecule — are being explored, with a dual GLP-1R/ gastric inhibitory ...